Suppr超能文献

通过招募和扩增感染端粒酶依赖性溶瘤病毒的肿瘤中的树突状细胞产生抗肿瘤免疫反应。

Antitumoral immune response by recruitment and expansion of dendritic cells in tumors infected with telomerase-dependent oncolytic viruses.

作者信息

Edukulla Ramakrishna, Woller Norman, Mundt Bettina, Knocke Sarah, Gürlevik Engin, Saborowski Michael, Malek Nisar, Manns Michael P, Wirth Thomas, Kühnel Florian, Kubicka Stefan

机构信息

Department of Gastroenterology, Medical School Hannover, Hannover, Germany.

出版信息

Cancer Res. 2009 Feb 15;69(4):1448-58. doi: 10.1158/0008-5472.CAN-08-1160. Epub 2009 Feb 3.

Abstract

Virotherapy can potentially be used to induce tumor-specific immune responses and to overcome tumor-mediated tolerance mechanisms because apoptotic tumor cells are exposed together with viral danger signals during oncolysis. However, insufficient numbers of dendritic cells (DC) present at the site of oncolysis can limit a tumor-specific immune response and the resulting therapeutic benefit. We investigated MHC class I peptide-specific immune responses against model antigens ovalbumin (OVA) and hemagglutinin (HA) in mouse tumor models that support efficient replication of the oncolytic adenovirus hTert-Ad. Virotherapy resulted in peptide-specific cytotoxic T-cell responses against intracellular tumor antigens. Triggering of DC and T-cell infiltration to the oncolytic tumors by macrophage inflammatory protein 1alpha (MIP-1alpha, CCL3) and Fms-like tyrosine kinase-3 ligand (Flt3L) enhanced both antitumoral and antiviral immune responses. Although immune-mediated clearance of the virus can restrict therapeutic efficacy of virotherapy, MIP-1alpha/FLT3L-augmented hTert-Ad virotherapy inhibited local tumor growth more effectively than virotherapy alone. In agreement with the hypothesis that immune-mediated mechanisms account for improved outcome in MIP-1alpha/FLT3L virotherapy, we observed systemic antitumoral effects by MIP-1alpha/FLT3L virotherapy on uninfected lung metastasis in immunocompetent mice but not in nude mice. Furthermore, MIP-1alpha/FLT3L virotherapy of primary tumors was strongly synergistic with tumor DC vaccination in inhibition of established lung metastasis. Combined viroimmunotherapy resulted in long-term survival of 50% of treated animals. In summary, improvement of cross-presentation of tumor antigens by triggering of DC and T-cell infiltration during virotherapy enhances antitumoral immune response that facilitates an effective viroimmunotherapy of primary tumors and established metastases.

摘要

溶瘤病毒疗法有潜力用于诱导肿瘤特异性免疫反应,并克服肿瘤介导的耐受机制,因为在肿瘤溶解过程中,凋亡的肿瘤细胞会与病毒危险信号一同暴露。然而,肿瘤溶解部位存在的树突状细胞(DC)数量不足,可能会限制肿瘤特异性免疫反应以及由此产生的治疗益处。我们在支持溶瘤腺病毒hTert-Ad高效复制的小鼠肿瘤模型中,研究了针对模型抗原卵清蛋白(OVA)和血凝素(HA)的MHC I类肽特异性免疫反应。溶瘤病毒疗法引发了针对细胞内肿瘤抗原的肽特异性细胞毒性T细胞反应。巨噬细胞炎性蛋白1α(MIP-1α,CCL3)和Fms样酪氨酸激酶-3配体(Flt3L)触发DC和T细胞浸润到溶瘤肿瘤中,增强了抗肿瘤和抗病毒免疫反应。尽管免疫介导的病毒清除会限制溶瘤病毒疗法的治疗效果,但MIP-1α/Flt3L增强的hTert-Ad溶瘤病毒疗法比单独的溶瘤病毒疗法更有效地抑制了局部肿瘤生长。与免疫介导机制导致MIP-1α/Flt3L溶瘤病毒疗法疗效改善的假设一致,我们观察到MIP-1α/Flt3L溶瘤病毒疗法对免疫健全小鼠未感染的肺转移瘤有全身抗肿瘤作用,而对裸鼠则无此作用。此外,原发性肿瘤的MIP-1α/Flt3L溶瘤病毒疗法与肿瘤DC疫苗接种在抑制已形成的肺转移方面具有很强的协同作用。联合病毒免疫疗法使50%的治疗动物长期存活。总之,在溶瘤病毒疗法期间通过触发DC和T细胞浸润来改善肿瘤抗原的交叉呈递,可增强抗肿瘤免疫反应,从而促进对原发性肿瘤和已形成转移瘤的有效病毒免疫治疗。

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验